<?xml version="1.0" encoding="UTF-8"?>
<p>Another anti-viral drug investigated by Gilead Sciences is remdesivir. The drug is believed to have potential activity against COVID-19 as “it has demonstrated in vitro and in vivo activity in animal models against MERS and SARS coronaviruses.” Gilead initiated two clinical trials on positive COVID-19 patients with mild and severe clinical manifestations separately. Patient enrolment started in February and it is anticipated for the results to be received in April [
 <xref rid="B25" ref-type="bibr">25</xref>].
</p>
